PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/12, 38/16, 39/245, 39/385 — A3

(11) International Publication Number: WO 99/58145

(43) International Publication Date: 18 November 1999 (18.11.99)

(21) International Application Number: PCT/GB99/01461

(22) International Filing Date: 10 May 1999 (10.05.99)

(30) Priority Data:

9809958.3	8 May 1998 (08.05.98)	GB
9811954.8	3 June 1998 (03.06.98)	GB
9812316.9	8 June 1998 (08.06.98)	GB

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF BRISTOL [GB/GB]; Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HIRST, Timothy, Raymond [GB/GB]; 30 Albert Road, Clevedon, North Somerset BS21 7RR (GB). WILLIAMS, Neil, Andrew [GB/GB]; 16 Old Coach Road, Cross, Axbridge, Somerset BS26 2EF (GB).

(74) Agent: NASH, David, Allan; Haseltine Lake & Co., Imperial House, 15–19 Kingsway, London WC2B 6UD (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 3 February 2000 (03.02.00)

(54) Title: IMMUNOMODULATORS FOR VACCINES

(57) Abstract

There is disclosed the use of: (i) EtxB, CtxB or VtxB free from whole toxin; (ii) an agent other than EtxB or CtxB, having GM1–binding activity, or an agent other than VtxB having Gb3–binding activity; or (iii) an agent having an effect on intracellular signalling events mediated by GM1–binding or Gb3 binding; as an immunomodulator for a vaccine against infectious diseases.